Annals of Surgical Oncology

, Volume 20, Issue 7, pp 2236–2241 | Cite as

Rare Breast Cancer: 933 Adenoid Cystic Carcinomas from the National Cancer Data Base

  • Nandini Kulkarni
  • Christopher M. Pezzi
  • Jon M. Greif
  • V. Suzanne Klimberg
  • Lisa Bailey
  • Soheila Korourian
  • Marlene Zuraek
Breast Oncology

Abstract

Background

Adenoid cystic carcinoma (ACC) is a rare subtype of breast malignancy.

Methods

Patients with ACC and infiltrating ductal carcinoma (IDC) reported to the National Cancer Data Base from 1998 to 2008 were reviewed for patient age, ethnicity, tumor size, nodal status, American Joint Committee on Cancer TNM Stage, tumor grade, initial treatment, hormone receptor status (for patients from 2004 to 2008), and survival (for patients from 1998 to 2003).

Results

A total of 933 patients with ACC and 729,938 with IDC were identified. No differences were found for incidence by race/ethnicity (p = 0.97). The group with ACC was older (median 60 vs. 58 years), had larger tumors (median 18 vs. 16 mm), had more grade 1 tumors (46 vs. 18 %), was less likely to undergo axillary lymph node evaluation (75.9 vs. 96.3 %), had fewer node-positive patients (5.1 vs. 35.5 %), had fewer estrogen receptor–positive tumors (15.4 vs. 75.6 %), had fewer progesterone receptor–positive tumors (13.3 vs. 65.2 %), and underwent breast-conserving surgery more often (69.8 vs. 59.8 %). Chemotherapy was provided less often for ACC (11.3 vs. 46.4 %), as was hormone therapy (9.1 vs. 42.3 %). All of these differences were statistically significant (p < 0.0001). With a median follow-up of 65.7 months (ACC) and 64.9 months (IDC), 5-year overall survival (OS) was 88 % for ACC vs. 84 % for IDC (p = 0.02). Grade 1 OS (ACC, 91 % vs. IDC, 92 %; p = 0.50) and stage I OS (ACC, 90 % vs. IDC, 91 %; p = 0.93) were equal.

Conclusions

Compared with IDC, ACC has different characteristics (lower grade, hormone receptor negative, node negative), is treated differently (less axillary surgery, fewer mastectomies, less chemotherapy, less hormone therapy), and has an improved prognosis, with 88 % 5-year survival.

Notes

Disclosure

The authors declare no conflict of interest.

References

  1. 1.
    Alis H, Yigitbas H, Kapan S, Kalayci M, Kilic G, Aygun E. Multifocal adenoid cystic carcinoma of the breast: an unusual presentation. Can J Surg. 2008;51:E36–7.PubMedGoogle Scholar
  2. 2.
    Billroth T. Die cylindergeschwalst. Untersuchungen ueber die entwicklung der blutgefasse. Berlin: G. Reimer; 1856.Google Scholar
  3. 3.
    Geschickter CF. Diseases of the breast: diagnosis, pathology, and treatment. Philadelphia: J. B. Lippincott; 1945.Google Scholar
  4. 4.
    Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res. 2010;12:R54.PubMedCrossRefGoogle Scholar
  5. 5.
    Marchiò C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast and salivary glands (or “The strange case of Dr. Jekyll and Mr. Hyde” of exocrine gland carcinomas). J Clin Pathol. 2010;63:220–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Azoulay S, Laé M, Fréneaux P, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol. 2005;18:1623–31.PubMedGoogle Scholar
  7. 7.
    Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65.PubMedCrossRefGoogle Scholar
  8. 8.
    Mastropasqua MG, Maiorano E, Pruneri G, et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol. 2005;18:1277–82.PubMedCrossRefGoogle Scholar
  9. 9.
    Crisi GM, Marconi SA, Makari-Judson G, Goulart RA. Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol. 2005;124:733–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Albores-Saavedra J, Heard SC, McLaren B, Kamino H, Witkiewicz AK. Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast. Am J Clin Pathol. 2005;123:866–73.PubMedCrossRefGoogle Scholar
  11. 11.
    Vranic S, Frkovic-Grazio S, Lamovec J, et al. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification. Hum Pathol. 2010;41:1617–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Wetterskog D, Lopez-Garcia MA, Lambros MB, et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol. 2012:226:84–96.PubMedCrossRefGoogle Scholar
  13. 13.
    Law YM, Quek ST, Tan PH, Wong SL. Adenoid cystic carcinoma of the breast. Singapore Med J. 2009;50:e8–11.PubMedGoogle Scholar
  14. 14.
    Kasagawa T, Suzuki M, Doki T, et al. Two cases of adenoid cystic carcinoma: preoperative cytological findings were useful in determining treatment strategy. Breast Cancer. 2006;13:112–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Anthony PP, James PD. Adenoid cystic carcinoma of the breast: prevalence, diagnostic criteria, and histogenesis. J Clin Pathol. 1975;28:647–55.PubMedCrossRefGoogle Scholar
  16. 16.
    Lim SK, Kovi J, Warner OG. Adenoid cystic carcinoma of breast with metastasis: a case report and review of the literature. J Natl Med Assoc. 1979;71:329–30.PubMedGoogle Scholar
  17. 17.
    Hopkins GB, Tullis RH. Adenoid cystic carcinoma of the breast. Calif Med. 1972;117:9–11.PubMedGoogle Scholar
  18. 18.
    Wilson WB, Spell JP. Adenoid cystic carcinoma of breast: a case with recurrence and regional metastasis. Ann Surg. 1967;166:861–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Glazebrook KN, Reynolds C, Smith RL, Gimenez EI, Boughey JC. Adenoid cystic carcinoma of the breast. Am J Roentgenol. 2010;194:1391–6.CrossRefGoogle Scholar
  20. 20.
    Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14:166–73.PubMedCrossRefGoogle Scholar
  21. 21.
    Sumpio BE, Jennings TA, Merino MJ, Sullivan PD. Adenoid cystic carcinoma of the breast. Data from the Connecticut Tumor Registry and a review of the literature. Ann Surg. 1987;205:295–301.PubMedCrossRefGoogle Scholar
  22. 22.
    Santamaria G, Velasco M, Zanón G,. Adenoid cystic carcinoma of the breast: mammographic appearance and pathologic correlation. Am J Roentgenol. 1998;171:1679–83.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Nandini Kulkarni
    • 1
  • Christopher M. Pezzi
    • 1
  • Jon M. Greif
    • 2
    • 3
  • V. Suzanne Klimberg
    • 4
  • Lisa Bailey
    • 2
    • 3
  • Soheila Korourian
    • 4
  • Marlene Zuraek
    • 5
  1. 1.Department of SurgeryAbington Memorial HospitalAbingtonUSA
  2. 2.Bay Area Breast Surgeons, Inc.OaklandUSA
  3. 3.Alta Bates Summit Medical CenterOaklandUSA
  4. 4.University of Arkansas for Medical SciencesLittle RockUSA
  5. 5.Stanford University Medical CenterPalo AltoUSA

Personalised recommendations